Sensei Biotherapeutics (SNSE)
(Delayed Data from NSDQ)
$0.63 USD
-0.01 (-1.30%)
Updated Aug 9, 2024 03:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Sensei Biotherapeutics, Inc. [SNSE]
Reports for Purchase
Showing records 1 - 6 ( 6 total )
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Abstract Data From Phase 1 Dose Escalation Study of SNS-101 in Advanced Solid Tumors May Be Underappreciated
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Topline Data for SNS-101 Phase 1 Dose Escalation Expected at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FY23 Results; Faster Than Projected Enrollment Leads to Earlier Topline Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Focusing on SNS-101 Phase 1/2 Trial; Pausing Other Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Taking a Strike at VISTA With a Conditionally Active Monoclonal Antibody; Initiating Coverage With a Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
|